Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy.
about
Biomarkers of Angiogenesis in Colorectal CancerQuantitative automated microscopy (QuAM) elucidates growth factor specific signalling in pain sensitizationLaser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild typePotential role of vascular targeted therapy to combat against tumor.Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials.Combined EGFR and VEGFR versus single EGFR signaling pathways inhibition therapy for NSCLC: a systematic review and meta-analysis.Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer.Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis.Delphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting EGFR/VEGFR2 signaling pathways.Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancerTargeted therapy in hepatocellular carcinomaTLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenograftsMulti-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy.Epidermal growth factor receptor as a major anticancer drug target.Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy.Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinomaInhibition of angiogenesis in the treatment of non-small cell lung cancer.Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancerIn vivo effect of an luteinizing hormone-releasing hormone analog on vascular endothelial growth factor and epidermal growth factor receptor expression in mammary tumorsBiomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs.S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.Preclinical pharmacodynamic evaluation of drug candidate SKLB-178 in the treatment of non-small cell lung cancer.Evolving strategies: future treatment of glioblastoma.Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice.Vandetanib in advanced non small cell lung cancer: a promise unfulfilled.Targeted medical therapy of biliary tract cancer: recent advances and future perspectives.Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives.Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer.Towards comprehensive characterization of HER2 overexpression.Expression of epidermal growth factor receptor and vascular endothelial growth factor in malignant canine epithelial nasal tumours.A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.Prognostic significance of cyclooxygenase-2, epidermal growth factor receptor 1, and microvascular density in gastric cancer.Strong radioprotective FGF1 signaling down-regulates proliferative and metastatic capabilities of the angiosarcoma cell line, ISOS-1, through the dual inhibition of EGFR and VEGFR pathways.Novel urinary exosomal biomarkers of acute T cell-mediated rejection in kidney transplant recipients: A cross-sectional study
P2860
Q26778891-B8C306EE-26A6-4D61-BBF8-359CCAE87BEAQ30497951-50E7E43B-188C-4BF6-94F6-C4D96DB3DBC8Q33358603-F801E384-94CD-47A5-8574-A800BC1AC95AQ33470615-2B3E383C-B838-460A-B94E-6AA18EF2D0C0Q34316070-D79824E6-64E0-48E4-A65D-357D77FF6171Q34390684-B8304F59-5DE2-433A-B23B-3799B4BA8846Q34433903-F3B1AD3E-3D5F-4280-AE8D-99982BD1D889Q34826532-3938C7B4-A8A9-484F-8613-DACD47833190Q35017125-599B9D7B-BB5B-4202-963F-F1655CD34ADEQ35198335-63D03C1B-7596-4DC1-8127-3DF97A9C1F4FQ35207561-EC9DCD15-822B-4D9C-AFF4-C8898D2E74C8Q35894601-DD33F276-B3AA-4B0F-BC0E-BBF72468A6CDQ36032533-4EC363C9-0EF4-443A-8A5E-D5FC6C62000FQ36614764-F9E5FBC3-1B1E-44CA-9FF5-7E9269EF5CD0Q36653667-7B71CF97-EA83-43B4-9C32-F7587EA84546Q36691776-8248C47B-C8CD-47D7-AC48-5D19792270DBQ36859958-CC3BF3F0-8C44-45D8-8DC0-ED1058F7932BQ36950548-121F9890-CF9D-4674-9F2A-E4CAACEAA2CEQ37125328-D8F03791-8948-4FA4-B0DC-0FA05533C6B5Q37235589-1AF548CF-A692-4D8D-8A91-EAA10AA31EFEQ37378581-96AD92E4-5357-4296-B0F1-89BB033D6CF7Q37522017-61023ACF-B0E8-4B2B-8747-EABE25AB98A3Q37594373-439BEABB-2A4E-40F6-B519-6323D724BAF6Q37706510-A03E0362-ADED-4747-9D37-B70E874AF0A8Q37862235-9BA7148A-B2D0-4341-A68A-25E344D410AAQ39543375-56484A3E-C96D-40F7-AD1D-BBA146B1298BQ41167117-221338CC-EAFB-4324-ADE5-D131626A8841Q42635172-DFDDD9B0-AD3E-4840-B4B6-C0A74E256F3BQ43097453-8FFF0EA1-25A1-4281-A29D-317CE83E5B40Q43141124-04F2787F-02EE-4BDF-916C-944E050EF136Q43147330-22141E4F-295B-46C0-81B9-4F21AA6E8EE8Q44877290-C9A4691C-71C7-4465-9993-813E4559D833Q48374393-DBAC66E5-CE6D-45C0-9CC5-F17CB59D4CC6Q51393573-694E98E3-EBEA-464A-8B24-9B17B8A46000Q55011926-B289FC98-9636-4223-8FEE-7CD6E5BAD854Q58727204-F6F497F4-1F3D-40C2-9125-5E705EB7420A
P2860
Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Interaction between the epider ...... lti-target anticancer therapy.
@ast
Interaction between the epider ...... lti-target anticancer therapy.
@en
Interaction between the epidermal growth factor receptor
@nl
type
label
Interaction between the epider ...... lti-target anticancer therapy.
@ast
Interaction between the epider ...... lti-target anticancer therapy.
@en
Interaction between the epidermal growth factor receptor
@nl
prefLabel
Interaction between the epider ...... lti-target anticancer therapy.
@ast
Interaction between the epider ...... lti-target anticancer therapy.
@en
Interaction between the epidermal growth factor receptor
@nl
P2093
P356
P1433
P1476
Interaction between the epider ...... lti-target anticancer therapy.
@en
P2093
E Martinelli
F Ciardiello
F Morgillo
M Orditura
M P Morelli
P304
P356
10.1093/ANNONC/MDL962
P478
17 Suppl 7
P577
2006-06-01T00:00:00Z